Methylprednisolone sodium succinate
( DrugBank: Methylprednisolone / KEGG DRUG: Methylprednisolone, Methylprednisolone acetate )
5 diseases
| 告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症/視神経脊髄炎 | 7 |
| 49 | 全身性エリテマトーデス | 1 |
| 50 | 皮膚筋炎/多発性筋炎 | 1 |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,685 / 薬物数 : 1,932 - (DrugBank : 355) / 標的遺伝子数 : 263 - 標的パスウェイ数 : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
49. 全身性エリテマトーデス
臨床試験数 : 1,227 / 薬物数 : 752 - (DrugBank : 175) / 標的遺伝子数 : 130 - 標的パスウェイ数 : 207
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
50. 皮膚筋炎/多発性筋炎
臨床試験数 : 231 / 薬物数 : 216 - (DrugBank : 55) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
51. 全身性強皮症
臨床試験数 : 639 / 薬物数 : 551 - (DrugBank : 157) / 標的遺伝子数 : 135 - 標的パスウェイ数 : 222
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
211. 左心低形成症候群
臨床試験数 : 23 / 薬物数 : 29 - (DrugBank : 11) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 13
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
